{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:47:08Z","timestamp":1785008828507,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019266","name":"Sierra Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clml.2021.07.016","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T08:29:49Z","timestamp":1627028989000},"page":"823-830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies"],"prefix":"10.1016","volume":"21","author":[{"given":"Wael","family":"Harb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal J.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Messmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Klencke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayad M.","family":"Al-Katib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.016_bib0001","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.coi.2007.05.004","article-title":"The Bcl-2-regulated apoptosis switch: mechanism and therapeutic potential","volume":"19","author":"Adams","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clml.2021.07.016_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ccr.2005.06.012","article-title":"Killing cancer cells by flipping the Bcl-2\/Bax switch","volume":"8","author":"Cory","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.07.016_bib0003","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.016_bib0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11523-018-0560-7","article-title":"Targeting BCL-2 in hematologic malignancies","volume":"13","author":"Khan","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2021.07.016_bib0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.016_bib0006","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.07.016_bib0007","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.016_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/npre.2009.3931.1","article-title":"MicroDNAs (MIDs) and transcriptional regulation","author":"Sheikhnejad","year":"2009","journal-title":"Nat Prec"},{"key":"10.1016\/j.clml.2021.07.016_bib0009","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.18632\/oncotarget.9872","article-title":"PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma","volume":"7","author":"Ebrahim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.07.016_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-014-2476-y","article-title":"Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide","volume":"74","author":"Rodrigueza","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2021.07.016_bib0011","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.07.016_bib0012","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.016_bib0013","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.016_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2021.07.016_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.016_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.016_bib0018","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-013-2361-0","article-title":"A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors","volume":"73","author":"Tolcher","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2021.07.016_bib0019","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.016_bib0020","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clml.2021.07.016_bib0021","series-title":"[package insert]. North","author":"Venclexta (venetoclax)","year":"2020"},{"key":"10.1016\/j.clml.2021.07.016_bib0022","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2021.07.016_bib0023","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1182\/blood-2007-02-071225","article-title":"Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice","volume":"109","author":"Raveche","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:20Z","timestamp":1761871100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2152265021002986"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}